Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Compugen Ltd. (CGEN) vs Keros Therapeutics, Inc. (KROS)

Compugen Ltd. and Keros Therapeutics, Inc. are both Biotechnology companies. Compugen Ltd. and Keros Therapeutics, Inc. are of similar size ($229.0M and $224.5M). Keros Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Compugen Ltd. trades at 6.3×. Compugen Ltd. grew revenue faster over the last twelve months: 234.2% against −84.6%. Compugen Ltd. has the higher net margin (47.6% vs 0.00%) and the higher return on invested capital (0.00% vs −1,345.3%). Across the 18 metrics below, Compugen Ltd. leads on 13 and Keros Therapeutics, Inc. on 5.

Valuation

Metric CGEN KROS Biotechnology median
P/E 6.26 n/m 7.88
P/S 3.04 6.97 11.47
P/B 2.54 0.88 2.52
Price to free cash flow 5.63 n/m 21.16
EV/EBITDA 3.30 0.26 0.74
EV/Sales 1.35 (0.79) 10.73
Earnings yield 15.97% (31.68%) (28.84%)
Free cash flow yield 17.78% (20.97%) (23.03%)

Profitability

Metric CGEN KROS Biotechnology median
Gross margin 86.89% 100.00% 65.16%
Operating margin 40.94% 0.00% 0.00%
Net margin 47.55% 0.00% 0.00%
Free cash flow margin 54.10% 0.00% 0.00%
Return on equity 47.85% (17.16%) (57.72%)
Return on assets 23.86% (15.92%) (49.22%)
Return on invested capital 0.00% (1,345.30%) 0.00%

Growth

Metric CGEN KROS Biotechnology median
Revenue growth (TTM) 234.18% (84.55%) 5.64%
EPS growth (last fiscal year) 337.50% 146.00% —
Revenue growth, 5-year CAGR 105.20% 89.45% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGEN KROS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.72 21.96 4.73
Net debt to EBITDA (4.65) (4.16) 0.96

Dividend

Metric CGEN KROS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CGEN KROS Biotechnology median
Market cap 224.51m 229.00m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack